{"url_path":"/sec/otlk/8-k/2026-06-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","accession_number":"0001104659-26-068659","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-068659-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":296,"has_tables":true,"body_markdown":"false\n0001649989\n\n0001649989\n\n2026-06-01\n2026-06-01\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13\nOR 15(d) of The Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date\nof earliest event reported):** **June 1, 2026**\n\n \n\n \n\n**Outlook Therapeutics,\nInc.**\n\n**(Exact name of registrant\nas specified in its charter)**\n\n \n\n \n\n**Delaware**\n**001-37759**\n**38-3982704**\n\n(State or other jurisdiction\n\nof incorporation)\n(Commission File Number)\n(IRS Employer Identification No.)\n\n \n\n**111\nS. Wood Avenue,****Unit\n#100**\n\n**Iselin, New Jersey**\n\n**08830**\n\n(Address of principal executive offices)\n(Zip Code)\n\n \n\nRegistrant's telephone number, including area code:\n**(609) 619-3990**\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n** **\n**Trading Symbol(s)**\n** **\n**Name of Each Exchange\non Which\nRegistered**\n\nCommon Stock\n \nOTLK\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}